Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04995274 SCHEMBL29385310 | 1.00 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2MCHR1 | |
| Pf-04995274 SCHEMBL619629 | 1.00 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2MCHR1 | |
| SCHEMBL2331352 | 0.96 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2DHFR | |
| SCHEMBL14138520 | 0.91 | HTR4 (0.90) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2333671 | 0.90 | HTR4 (0.92) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2333665 | 0.90 | HTR4 (0.92) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL5116742 | 0.89 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2335982 | 0.89 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2335647 | 0.85 | HTR4 (0.78) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2334363 | 0.85 | HTR4 (0.78) | HTR4CYP3A4ACHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2536713-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | Pfizer Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | claimed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | claimed |
| EP-2536713-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | Pfizer Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2536713-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | Pfizer Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2536713-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | Pfizer Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-102762554-A | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors | PFIZER | 2012-10-31 | — | — | CN | disclosed |
| CN-102762554-A | (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors | PFIZER | 2012-10-31 | — | — | CN | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011101774-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | PFIZER INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041026-A1 | (R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS | HTR4, HTR1A, HTR3B | HTR4 1/4885CYP3A4 369/4885ACHE 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.